Literature DB >> 1184760

Asymptomatic liver disease in haemophiliacs.

P M Mannucci, A Capitanio, E Del Ninno, M Colombo, F Pareti, Z M Ruggeri.   

Abstract

The incidence of jaundice and of abnormal liver function tests has been assessed in 91 multitransfused patients with severe haemophilia A and B. Tests of hepatocyte function were within the normal range in the majority of patients. On the contrary, tests of biliary cell function, liver cell damage, and bromsulphthalein retention gave high rates of abnormal values, which tended to increase with age. Hepatitis B surface antigen was present in 8% and the corresponding antibody in 66% of the cases; 18% had a history of jaundice. All patients were asymptomatic and only a minority showed clinical signs of liver involvement. These data suggest that in haemophilacs repeated and prolonged contact with the agent(s) responsible for post-transfusion hepatitis may cause chronic liver damage not associated with overt illness.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1184760      PMCID: PMC475789          DOI: 10.1136/jcp.28.8.620

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  15 in total

1.  Editorial: Tolerating hepatitis.

Authors:  G Grady
Journal:  N Engl J Med       Date:  1974-07-11       Impact factor: 91.245

2.  Jaundice and hepatitis B antigen-antibody in hemophilia.

Authors:  J H Lewis; N G Maxwell; J M Brandon
Journal:  Transfusion       Date:  1974 May-Jun       Impact factor: 3.157

3.  Liver diseases in asymptomatic carriers of hepatitis B antigen.

Authors:  J B Simon; S K Patel
Journal:  Gastroenterology       Date:  1974-05       Impact factor: 22.682

4.  Antibody to hepatitis B antigen in haemophiliacs and their household contacts.

Authors:  C J Burrell; A C Parker; D M Ramsay; E Proudfoot
Journal:  J Clin Pathol       Date:  1974-04       Impact factor: 3.411

5.  Asymptomatic liver disease in hepatitis B antigen carriers.

Authors:  I L Woolf; B E Boyes; D M Jones; J S Whittaker; E Tapp; R N MacSween; P H Renton; F Stratton; I W Dymock
Journal:  J Clin Pathol       Date:  1974-05       Impact factor: 3.411

6.  Jaundice and antibodies directed against factors 8 and 9 in patients treated for haemophilia or Christmas disease in the United Kingdom.

Authors:  R Biggs
Journal:  Br J Haematol       Date:  1974-03       Impact factor: 6.998

7.  Detection of antibody to hepatitis-associated antigen in hemophilia patients and in voluntary blood donors.

Authors:  M R Peterson; L F Barker; D S Schade
Journal:  Vox Sang       Date:  1973-01       Impact factor: 2.144

8.  Hepatitis and clotting-factor concentrates.

Authors:  C K Kasper; S A Kipnis
Journal:  JAMA       Date:  1972-07-31       Impact factor: 56.272

9.  Rapid detection of Australia antigen by counterimmunoelectrophoresis.

Authors:  D J Gocke; C Howe
Journal:  J Immunol       Date:  1970-04       Impact factor: 5.422

10.  Serum enzyme changes after intramuscular bleeding in patients with haemophilia and Christmas disease.

Authors:  C D Forbes; J King; C R Prentice; G P McNicol
Journal:  J Clin Pathol       Date:  1972-12       Impact factor: 3.411

View more
  13 in total

Review 1.  Gene therapy for hemophilia: what does the future hold?

Authors:  Bhavya S Doshi; Valder R Arruda
Journal:  Ther Adv Hematol       Date:  2018-08-27

2.  Inactivation of HIV in plasma derivatives by beta-propiolactone and UV irradiation.

Authors:  H Dichtelmüller; W Stephan; A M Prince; L Gürtler; F Deinhardt
Journal:  Infection       Date:  1987       Impact factor: 3.553

3.  Viral exposure and abnormal liver function in haemophilia.

Authors:  B A McVerry; M G Ross; W A Knowles; J Voke
Journal:  J Clin Pathol       Date:  1979-04       Impact factor: 3.411

4.  A clinicopathological study of liver disease in haemophiliacs.

Authors:  P M Mannucci; G Ronchi; L Rota; M Colombo
Journal:  J Clin Pathol       Date:  1978-08       Impact factor: 3.411

5.  Multiple-dose pharmacokinetics of oral zidovudine in hemophilia patients with human immunodeficiency virus infection.

Authors:  G D Morse; A Portmore; J Olson; C Taylor; C Plank; R C Reichman
Journal:  Antimicrob Agents Chemother       Date:  1990-03       Impact factor: 5.191

6.  Liver disease complicating severe haemophilia in childhood.

Authors:  K M McGrath; J S Lilleyman; D R Triger; J C Underwood
Journal:  Arch Dis Child       Date:  1980-07       Impact factor: 3.791

7.  Non-invasive investigation of liver disease in haemophilic patients.

Authors:  E J Miller; C A Lee; P Karayiannis; S J Hamilton-Dutoit; R Dick; H C Thomas; P B Kernoff
Journal:  J Clin Pathol       Date:  1988-10       Impact factor: 3.411

8.  Immune complexes and abnormal liver function in haemophilia.

Authors:  B A McVerry; J Voke; I Mohammed; K M Dormandy; E J Holborow
Journal:  J Clin Pathol       Date:  1977-12       Impact factor: 3.411

9.  Coagulation factor therapy for hemophilia: relation to hepatitis B and to liver function.

Authors:  R T Card; M Dusevic; B E Lukie
Journal:  Can Med Assoc J       Date:  1982-01-01       Impact factor: 8.262

10.  Intravenous and oral zidovudine pharmacokinetics and coagulation effects in asymptomatic human immunodeficiency virus-infected hemophilia patients.

Authors:  G D Morse; A C Portmore; V Marder; C Plank; J Olson; C Taylor; W Bonnez; R C Reichman
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.